mp.weixin.qq.com·· 6 hours agoPickScore90
NATALEE Six-Year Follow-up Shows Kisqali Plus Endocrine Therapy Cuts Death Risk 19% in High-Risk HR+/HER2- Early Breast Cancer
In brief
Novartis announced six-year follow-up results from the phase 3 NATALEE trial. In patients with high recurrence risk HR+/HER2- early breast cancer, Kisqali (ribociclib) plus endocrine therapy reduced the risk of death by 19% compared with endocrine therapy alone (HR=0.809, 95% CI 0.661-0.989).
Why it matters
The brief gives the six-year overall survival hazard ratio and confidence interval, letting readers compare adjuvant data across CDK4/6 inhibitors.
Source: mp.weixin.qq.com · mp.weixin.qq.com